We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Irras Ab | LSE:0GDW | London | Ordinary Share | SE0008321202 | IRRAS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.038 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
STOCKHOLM, Oct. 11, 2022 /PRNewswire/ -- IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the launch of a new educational webinar series, 'Exploring the Impact of IRRAflow's Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage', with the Jacobs Institute.
During each live webinar, Dr. Adnan Siddiqui, Chief Executive Officer and Chief Medical Officer of the Jacobs Institute, will moderate a panel of neurosurgeon experts in a 60-minute interactive discussion around new treatments for intracranial hemorrhage. Physician panelists and topics will vary with each webinar, but the overall subject will focus on the benefits of utilizing IRRAflow's active fluid exchange to quickly and efficiently clear blood from the intraventricular space.
During each episode of the webinar series, Dr. Siddiqui and an esteemed group of expert panelists will discuss the historical shortcomings of traditional treatment for patients with intracranial bleeding and how new technological advances, such as IRRAS' IRRAflow system, expand the options available to treat this challenging patient population. In addition, each physician panelist will discuss their experience incorporating IRRAflow into their clinical practice and share their recently published IRRAflow case reviews and ongoing clinical studies.
"We are excited to partner with the Jacobs Institute, Dr. Siddiqui, and the University of Buffalo Department of Neurosurgery to bring together leading experts to discuss the evolution in treatment for intracranial bleeding," said Will Martin, President and CEO of IRRAS. "Dr. Siddiqui and his peers in Buffalo are world-renowned for their contribution to advancing innovation in the treatment of stroke, and we feel that this webinar series will create an ideal learning environment where experts share advice with their peers regarding cutting-edge technology, and lessons learned during clinical practice."
The IRRAflow Webinar Series
Title: Exploring the Impact of IRRAflow's Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage
Date: Tuesday, October 25th
Time: 5 pm EST
Moderator: Adnan H. Siddiqui, MD, Ph.D., CEO/CMO of the Jacobs Institute, Professor and Vice Chairman of the University of Buffalo Department of Neurosurgery (UBNS), and Director of Neurosurgical Stroke Service for Kaleida Health
Panelists:
Register Here: https://jacobsinstitute-org.zoom.us/webinar/register/WN_HieJpGtATlO2Z7zfvhYTiQ
About The Jacobs Institute
The Jacobs Institute is a non-profit organization whose mission is to accelerate the development of next-generation technologies in vascular medicine through collisions of physicians, engineers, entrepreneurs, and industry. The JI's vision is to improve the treatment of vascular disease in Western New York and the world, while fostering local economic development. The JI fosters medical collaboration and innovation through partnerships with the University at Buffalo (UB), Kaleida Health, and industry, to be a fitting tribute to the work and memory of Lawrence D. Jacobs, M.D.
To learn more about the Jacobs Institute, please visit our website at: https://jacobsinstitute.org.
About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on October 11, 2022, at 8:30 (CET).
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/irras/r/irras-announces-new-educational-webinar-series-in-collaboration-with-the-jacobs-institute-and-the-un,c3645915
View original content:https://www.prnewswire.co.uk/news-releases/irras-announces-new-educational-webinar-series-in-collaboration-with-the-jacobs-institute-and-the-university-of-buffalo-department-of-neurosurgery-301645536.html
Copyright 2022 PR Newswire
1 Year Irras Ab Chart |
1 Month Irras Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions